Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults
- PMID: 8971551
Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults
Abstract
The goal of our study was to compare the clinical usefulness of plasma insulin-like growth factor-I (IGF-I) (with and without binding protein extraction) and IGF binding protein-3 (IGFBP-3) measurements in the diagnosis of growth hormone (GH) disorders in adults. IGF-I and IGFBP-3 concentrations were measured in 25 acromegalic and 25 GH-deficient adult (GHDA) subjects (20-76 years) by comparison to a control population (n = 81) after age and sex stratification. In untreated acromegaly, IGF-I and IGFBP-3 were clearly increased (10 times the mean of controls for unextracted IGF-I, 4 times for extracted IGF-I and 2 times for IGFBP-3). Using the mean + 2SD of the control population as the cut-off point, the sensitivity of IGF-I for the diagnosis of acromegaly was higher than that of IGFBP-3 (unextracted IGF-I: 96% and extracted IGF-I: 100% vs IGFBP-3: 76%). In GHDAs, IGF-I and IGFBP-3 were decreased (34% of the mean of controls for unextracted IGF-I, 37% for extracted IGF-I and 70% for IGFBP-3). Using the mean - 2SD of the control population as the cut-off point, the sensitivity of IGF-I measurement for the diagnosis of GHDA was relatively low, but better for unextracted (68%) than for extracted IGF-I (52%). The sensitivity of IGFBP-3 was much lower (36%), thus invalidating this parameter for the diagnosis of GHDA. Our observations demonstrate that IGF-I measurement is a more powerful tool than IGFBP-3 measurement for the diagnosis of GH disorders in adults. Both IGF-I and IGFBP-3 are very useful for the diagnosis of acromegaly, but they are less reliable for diagnosing GHDA, as normal IGF-I or IGFBP-3 values do not rule out GH deficiency.
Similar articles
-
IGF-1 and IGFBP-3 screening for disorders of growth hormone secretion.N Z Med J. 1996 May 10;109(1021):156-9. N Z Med J. 1996. PMID: 8657365
-
[Usefulness of the measurement of insulin-like growth factor (IGF-I) and IGF-1 binding protein-3 (IGFBP-3) for the diagnosis of growth hormone (GH) deficiency in children].Rev Med Chil. 1999 Jul;127(7):807-13. Rev Med Chil. 1999. PMID: 10668288 Spanish.
-
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.Clin Endocrinol (Oxf). 2004 Jul;61(1):138-44. doi: 10.1111/j.1365-2265.2004.02064.x. Clin Endocrinol (Oxf). 2004. PMID: 15212656
-
Diagnosis and endocrine testing in acromegaly.Endocrinol Metab Clin North Am. 1992 Sep;21(3):649-68. Endocrinol Metab Clin North Am. 1992. PMID: 1521517 Review.
-
[Somatomedins and their significance in pediatrics].Klin Padiatr. 1985 Sep-Oct;197(5):378-85. doi: 10.1055/s-2008-1034009. Klin Padiatr. 1985. PMID: 3906254 Review. German.
Cited by
-
IGF-I measurements in the diagnosis of adult growth hormone deficiency.Pituitary. 2007;10(2):151-7. doi: 10.1007/s11102-007-0028-8. Pituitary. 2007. PMID: 17429593 Review.
-
A risk-benefit assessment of octreotide in the treatment of acromegaly.Drug Saf. 1997 Nov;17(5):317-24. doi: 10.2165/00002018-199717050-00004. Drug Saf. 1997. PMID: 9391775 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous